Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Bayesian adaptive randomization
Bedaquiline
Clofazimine
Delamanid
Fluoroquinolone
Linezolid
MDR-TB
Non-inferiority
Pyrazinamide
Rifampicin-resistant tuberculosis
Rifampin-resistant tuberculosis
Treatment shortening
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
25 Sep 2021
25 Sep 2021
Historique:
received:
08
03
2021
accepted:
27
07
2021
entrez:
26
9
2021
pubmed:
27
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. While most MDR/RR-TB patients do not receive treatment, many who do are treated for 18 months or more. A shorter all-oral regimen is currently recommended for only a sub-set of MDR/RR-TB. Its use is only conditionally recommended because of very low-quality evidence underpinning the recommendation. Novel combinations of newer and repurposed drugs bring hope in the fight against MDR/RR-TB, but their use has not been optimized in all-oral, shorter regimens. This has greatly limited their impact on the burden of disease. There is, therefore, dire need for high-quality evidence on the performance of new, shortened, injectable-sparing regimens for MDR-TB which can be adapted to individual patients and different settings. endTB is a phase III, pragmatic, multi-country, adaptive, randomized, controlled, parallel, open-label clinical trial evaluating the efficacy and safety of shorter treatment regimens containing new drugs for patients with fluoroquinolone-susceptible, rifampin-resistant tuberculosis. Study participants are randomized to either the control arm, based on the current standard of care for MDR/RR-TB, or to one of five 39-week multi-drug regimens containing newly approved and repurposed drugs. Study participation in all arms lasts at least 73 and up to 104 weeks post-randomization. Randomization is response-adapted using interim Bayesian analysis of efficacy endpoints. The primary objective is to assess whether the efficacy of experimental regimens at 73 weeks is non-inferior to that of the control. A sample size of 750 patients across 6 arms affords at least 80% power to detect the non-inferiority of at least 1 (and up to 3) experimental regimens, with a one-sided alpha of 0.025 and a non-inferiority margin of 12%, against the control in both modified intention-to-treat and per protocol populations. The lack of a safe and effective regimen that can be used in all patients is a major obstacle to delivering appropriate treatment to all patients with active MDR/RR-TB. Identifying multiple shorter, safe, and effective regimens has the potential to greatly reduce the burden of this deadly disease worldwide. ClinicalTrials.gov Identifier NCT02754765. Registered on 28 April 2016; the record was last updated for study protocol version 3.3, on 27 August 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. While most MDR/RR-TB patients do not receive treatment, many who do are treated for 18 months or more. A shorter all-oral regimen is currently recommended for only a sub-set of MDR/RR-TB. Its use is only conditionally recommended because of very low-quality evidence underpinning the recommendation. Novel combinations of newer and repurposed drugs bring hope in the fight against MDR/RR-TB, but their use has not been optimized in all-oral, shorter regimens. This has greatly limited their impact on the burden of disease. There is, therefore, dire need for high-quality evidence on the performance of new, shortened, injectable-sparing regimens for MDR-TB which can be adapted to individual patients and different settings.
METHODS
METHODS
endTB is a phase III, pragmatic, multi-country, adaptive, randomized, controlled, parallel, open-label clinical trial evaluating the efficacy and safety of shorter treatment regimens containing new drugs for patients with fluoroquinolone-susceptible, rifampin-resistant tuberculosis. Study participants are randomized to either the control arm, based on the current standard of care for MDR/RR-TB, or to one of five 39-week multi-drug regimens containing newly approved and repurposed drugs. Study participation in all arms lasts at least 73 and up to 104 weeks post-randomization. Randomization is response-adapted using interim Bayesian analysis of efficacy endpoints. The primary objective is to assess whether the efficacy of experimental regimens at 73 weeks is non-inferior to that of the control. A sample size of 750 patients across 6 arms affords at least 80% power to detect the non-inferiority of at least 1 (and up to 3) experimental regimens, with a one-sided alpha of 0.025 and a non-inferiority margin of 12%, against the control in both modified intention-to-treat and per protocol populations.
DISCUSSION
CONCLUSIONS
The lack of a safe and effective regimen that can be used in all patients is a major obstacle to delivering appropriate treatment to all patients with active MDR/RR-TB. Identifying multiple shorter, safe, and effective regimens has the potential to greatly reduce the burden of this deadly disease worldwide.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov Identifier NCT02754765. Registered on 28 April 2016; the record was last updated for study protocol version 3.3, on 27 August 2019.
Identifiants
pubmed: 34563240
doi: 10.1186/s13063-021-05491-3
pii: 10.1186/s13063-021-05491-3
pmc: PMC8465691
doi:
Substances chimiques
Antitubercular Agents
0
Pharmaceutical Preparations
0
Rifampin
VJT6J7R4TR
Banques de données
ClinicalTrials.gov
['NCT02754765']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
651Subventions
Organisme : NIAID NIH HHS
ID : K08 AI141740
Pays : United States
Organisme : NIAID NIH HHS
ID : L30 AI120170
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Antimicrob Agents Chemother. 2011 Oct;55(10):4499-505
pubmed: 21768515
Eur Respir J. 2013 Jun;41(6):1393-400
pubmed: 23018916
Antimicrob Agents Chemother. 2011 Dec;55(12):5485-92
pubmed: 21930883
PLoS One. 2013 May 07;8(5):e63057
pubmed: 23667572
Am J Respir Crit Care Med. 2013 Jul 1;188(1):97-102
pubmed: 23593945
Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92
pubmed: 20442432
Health Qual Life Outcomes. 2019 May 31;17(1):94
pubmed: 31151398
Open Forum Infect Dis. 2019 Mar 29;6(4):ofz152
pubmed: 31041349
Clin Infect Dis. 2019 Apr 24;68(9):1522-1529
pubmed: 30165431
Eur Respir J. 2020 Mar 20;55(3):
pubmed: 31862767
Int J Tuberc Lung Dis. 2014 Oct;18(10):1188-94
pubmed: 25216832
Int J Tuberc Lung Dis. 1999 Oct;3(10 Suppl 2):S231-79
pubmed: 10529902
J Exp Med. 1956 Nov 1;104(5):763-802
pubmed: 13367342
Int J Tuberc Lung Dis. 2010 Mar;14(3):275-81
pubmed: 20132617
Antimicrob Agents Chemother. 2007 Mar;51(3):1011-5
pubmed: 17178794
Am J Respir Crit Care Med. 2016 Oct 15;194(8):1029-1031
pubmed: 27685538
Int J Tuberc Lung Dis. 2004 Nov;8(11):1382-4
pubmed: 15581210
Lancet Respir Med. 2020 Apr;8(4):383-394
pubmed: 32192585
Am J Respir Crit Care Med. 2021 Jan 1;203(1):111-119
pubmed: 32706644
N Engl J Med. 2020 Mar 5;382(10):893-902
pubmed: 32130813
J Bras Pneumol. 2009 Jan;35(1):54-62
pubmed: 19219331
Clin Infect Dis. 2010 Jul 1;51(1):6-14
pubmed: 20504231
Am J Ther. 2016 Mar-Apr;23(2):e521-30
pubmed: 24284652
Lancet Respir Med. 2019 Dec;7(12):999-1000
pubmed: 31732486
Int J Tuberc Lung Dis. 2016 Dec 1;20(12):8-12
pubmed: 28240566
Int J Tuberc Lung Dis. 2010 Feb;14(2):241-2
pubmed: 20074418
Int J Tuberc Lung Dis. 2012 Apr;16(4):447-54
pubmed: 22325685
Eur Respir J. 2012 Dec;40(6):1430-42
pubmed: 22496332
N Engl J Med. 2012 Jun 7;366(23):2151-60
pubmed: 22670901
N Engl J Med. 2019 Mar 28;380(13):1201-1213
pubmed: 30865791
Int J Tuberc Lung Dis. 2015 May;19(5):517-24
pubmed: 25868018
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30012767
J Antimicrob Chemother. 2014 Nov;69(11):3103-7
pubmed: 24986495
PLoS Med. 2019 Mar 22;16(3):e1002767
pubmed: 30901331
N Engl J Med. 2012 Oct 18;367(16):1508-18
pubmed: 23075177
Eur Respir J. 2018 Dec 20;52(6):
pubmed: 30361246
Int J Tuberc Lung Dis. 2014 Feb;18(2):160-7
pubmed: 24429307
Clin Trials. 2017 Feb;14(1):17-28
pubmed: 27559021
N Engl J Med. 2014 Aug 21;371(8):723-32
pubmed: 25140958
Eur Respir J. 2015 Jan;45(1):161-70
pubmed: 25234807
Am J Respir Crit Care Med. 2005 Apr 1;171(7):699-706
pubmed: 15709048
Lancet Respir Med. 2015 Dec;3(12):963-72
pubmed: 26597127
Lancet Respir Med. 2019 Mar;7(3):249-259
pubmed: 30630778
Int J Tuberc Lung Dis. 2016 Feb;20(2):177-86
pubmed: 26792469
Antimicrob Agents Chemother. 2012 Jun;56(6):3114-20
pubmed: 22470112
Eur Respir J. 2016 Nov;48(5):1503-1507
pubmed: 27587544
Int J Tuberc Lung Dis. 2014 Oct;18(10):1180-7
pubmed: 25216831
Bull World Health Organ. 2014 Jan 1;92(1):68-74
pubmed: 24391302
Int J Tuberc Lung Dis. 2006 Apr;10(4):402-8
pubmed: 16602404
J Clin Epidemiol. 2015 Jun;68(6):703-7
pubmed: 25578218
Eur Respir J. 2011 Sep;38(3):516-28
pubmed: 21828024
N Engl J Med. 2015 Jul 16;373(3):290-1
pubmed: 26176401
Expert Rev Anti Infect Ther. 2020 Aug;18(8):701-704
pubmed: 32345064
Clin Infect Dis. 2015 May 1;60(9):1361-7
pubmed: 25605283
Eur Respir J. 2016 Feb;47(2):564-74
pubmed: 26647431